Case Study: Chronic Candida and Metabolic Syndrome in a 45-Year-Old Man — Yeast Eradication, Blood Sugar Stabilisation, and Weight Loss Using the Functional Health Matrix

Illustrative composite — not a single patient. This case study is a teaching composite synthesised from anonymised patterns in the published clinical literature and Nutri-Link case-history references. It does not describe a specific identifiable patient seen by Codenutri Ltd or any single practitioner. Names, demographic specifics, and quoted dialogue are constructed for educational illustration. Always work with a registered clinician for individual care. Editorial review by Chris Massamba, Dip CNM, FMCHC.

Patient Presentation

David (not his real name), a 45-year-old IT project manager from Manchester, presented to the clinic in February 2026 with a constellation of symptoms that had been dismissed piecemeal by his NHS GP over the preceding four years. His presenting complaint, in his own words: "I've been told I've got metabolic syndrome — whatever that means — but no one's explained why a fit-ish 45-year-old bloke suddenly has the blood work of a 65-year-old. I've put on two stone in three years, mostly around my belly. I'm exhausted by 3 p.m. every day. My sugar cravings are uncontrollable — I can eat a whole packet of biscuits without thinking. And I've had this white coating on my tongue for months. The GP gave me fluconazole twice. It cleared up for a fortnight, then came straight back. No one's asked what I'm eating or what's going on in my gut."

David's symptom timeline revealed a cascade pattern. In 2019, he completed two consecutive courses of broad-spectrum antibiotics (clarithromycin, then co-amoxiclav) for a persistent chest infection. Within weeks of finishing the second course, he developed new-onset bloating, sugar cravings that felt "almost addictive," and the first appearance of oral thrush. Over the following eighteen months, his weight climbed from 82 kg to 94 kg, his waist circumference expanded to 108 cm, and routine blood work at his NHS health check revealed fasting glucose of 6.7 mmol/L, triglycerides of 2.9 mmol/L, and HDL cholesterol of 0.9 mmol/L — meeting three of the five NCEP ATP III criteria for metabolic syndrome. His blood pressure had crept to 148/92 mmHg.

He reported intermittent fungal nail infections on both great toes (present for two years, unresponsive to topical terbinafine), perianal itching, and what he described as "fuzzy thinking — like there's cotton wool between me and the world." He worked 55-hour weeks, ate lunch at his desk (typically a supermarket meal deal), drank four to five pints of lager on Friday and Saturday evenings, and relied on sugary snacks to power through afternoon energy crashes. His GP had prescribed metformin 500 mg twice daily eighteen months earlier, but David had discontinued it after six weeks due to gastrointestinal side effects.

Initial Clinical Assessment

Using the Stewart Nutrition deficiency symptom screening by body system, I systematically assessed David for nutritional insufficiencies contributing to his clinical picture:

General appearance: Central adiposity with relatively preserved limb musculature — the classic pattern of visceral fat deposition driven by insulin resistance. Fatigue described as "heavy, not sleepy — like my body is wading through treacle" — pattern consistent with magnesium, B-vitamin (especially B1 and B12), and protein-energy insufficiency superimposed on mitochondrial inefficiency.

Mouth and mucous membranes: Persistent white coating on the dorsum of the tongue (scrapable, consistent with oral candidiasis), angular cheilitis at the left corner of the mouth, and a history of recurrent aphthous ulcers — classic signs of iron, riboflavin (B2), and possibly B12 deficiency (Stewart Nutrition reference: sore tongue, cracking at corners of mouth). The mouth was a visible biomarker of the gut ecosystem below.

Skin and nails: Onychomycosis (both halluces, distal subungual pattern), dry skin on shins and elbows, seborrhoeic dermatitis at the nasolabial folds — suggestive of essential fatty acid deficiency and zinc insufficiency. The fungal nail involvement indicated systemic candidal burden rather than isolated topical infection.

Digestive system: Post-prandial bloating within 20 minutes of eating, erratic bowel habits (predominantly constipation with occasional loose stools), sugar cravings described as "not a preference — a compulsion," and history of antibiotic-associated gut disruption. This picture was highly consistent with small intestinal fungal overgrowth (SIFO) driving both local GI symptoms and systemic metabolic effects through gut permeability and mycobiome-mediated immune activation.

Energy and metabolic systems: Profound post-prandial somnolence, 3 p.m. energy crash requiring sugar to "reboot," cold hands and feet despite normothermia — indicative of reactive hypoglycaemia, chromium insufficiency, and mitochondrial substrate delivery failure.

Nervous system: Brain fog characterised as "processing lag — I read the same email three times before it sinks in," poor concentration, occasional tingling in the fingertips — suggestive of B12 insufficiency (possibly compounded by metformin exposure) and glycaemic variability affecting cerebral glucose delivery.

Musculoskeletal system: Intermittent calf cramps at night (2-3 times weekly), muscle fatigue disproportionate to physical demand — classic magnesium and potassium deficiency indicators per the Stewart Nutrition framework.

The clinical picture formed a coherent narrative: antibiotic-induced gut dysbiosis had permitted Candida albicans overgrowth, which had driven intestinal permeability, systemic low-grade inflammation, and progressive insulin resistance. The resulting hyperglycaemia and hyperinsulinaemia had created a glucose-rich mucosal environment that further favoured yeast proliferation — a self-reinforcing pathogenic loop. The metabolic syndrome diagnosis was downstream of the gut mycobiome disturbance, not an independent condition.

Functional Health Matrix Assessment

I scored David across all seven nodes of the Functional Health Matrix, with 1 representing severe dysfunction and 5 representing optimal function:

Total Initial Matrix Score: 12/35 — moderate-to-severe dysfunction with the Assimilation, Communication, and Energy Production nodes as the interconnected therapeutic priorities. The gut mycobiome was the origin; insulin resistance was the amplifier.

Wheel of Life Assessment

Total Initial Wheel of Life Score: 31/80 — pronounced imbalance across the physical health domains, with Nutrition, Stress Management, and Movement as the most dysfunctional dimensions requiring immediate attention.

Functional Testing Ordered

Based on the clinical presentation and matrix assessment, I ordered the following functional investigations:

GI-MAP Comprehensive Stool Analysis (Diagnostic Solutions Laboratory):

• Candida albicans: 3.8 × 10³ (elevated; reference <1.0 × 10³)
• Candida spp.: 4.2 × 10³ (elevated; reference <1.0 × 10³)
• Faecal zonulin: 158 ng/mL (elevated; reference <107 ng/mL) — indicating increased intestinal permeability
• Faecal secretory IgA: 412 µg/g (low-normal; reference 500-2,040 µg/g) — suggesting mucosal immune depression
• Bacteroidetes/Firmicutes ratio: markedly shifted towards Firmicutes with reduced diversity — dysbiosis pattern associated with obesity and insulin resistance
• Elastase-1: 310 µg/g (adequate; reference >200 µg/g) — pancreatic exocrine function preserved
• β-glucuronidase: elevated at 5,280 U/g (reference <3,600 U/g) — impaired Phase II detoxification and oestrogen recirculation

Comprehensive Metabolic Panel (fasting):

• Fasting glucose: 6.7 mmol/L (impaired; optimal <5.6 mmol/L)
• HbA1c: 44 mmol/mol / 6.2% (prediabetic range; optimal <37 mmol/mol)
• Fasting insulin: 18.2 µIU/mL (elevated; optimal <8 µIU/mL)
• HOMA-IR: 4.8 (severe insulin resistance; optimal <1.7)
• Triglycerides: 2.9 mmol/L (elevated; optimal <1.7 mmol/L)
• HDL cholesterol: 0.9 mmol/L (low; optimal >1.0 mmol/L for men)
• ALT: 52 U/L (mildly elevated; optimal <35 U/L)
• hs-CRP: 4.8 mg/L (elevated; optimal <1.0 mg/L)
• Uric acid: 428 µmol/L (high-normal; optimal <360 µmol/L)

Nutritional Assessment:

• Serum magnesium (RBC): 1.58 mmol/L (low; optimal 1.8-2.5 mmol/L)
• Serum zinc: 11.2 µmol/L (low-normal; optimal 13-18 µmol/L)
• Vitamin D (25-OH): 42 nmol/L (insufficient; optimal 100-150 nmol/L — NICE reference >50 nmol/L for adequacy but this is a bone-centric threshold)
• Serum B12: 268 pg/mL (low-normal; optimal >500 pg/mL per functional medicine ranges)
• Serum ferritin: 89 µg/L (adequate; optimal 100-150 µg/L with hs-CRP context — likely depressed by inflammatory block)

Urinary Organic Acids (Great Plains Laboratory — OAT):

• D-Arabinitol: 72 mmol/mol creatinine (elevated; reference <29) — a fungal metabolite confirming significant intestinal yeast overgrowth
• Tartaric acid: 86 mmol/mol creatinine (elevated; reference <22) — further yeast marker
• Citramalic acid: elevated — yeast/clostridial marker

The testing confirmed the clinical hypothesis with precision: significant intestinal Candida overgrowth (SIFO pattern) with elevated fungal metabolites, confirmed intestinal permeability (elevated zonulin), depressed mucosal immunity (low sIgA), severe insulin resistance (HOMA-IR 4.8), and multiple nutritional deficiencies consistent with the Stewart Nutrition screening. The β-glucuronidase elevation suggested impaired detoxification capacity that would need to be addressed in Phase 2.

Intervention Protocol

The protocol was structured across three phases, sequenced to avoid overwhelming David's detoxification capacity whilst addressing the root drivers systematically.

Phase 1: Remove and Stabilise (Weeks 1-4)

Dietary Intervention — Anti-Candida Nutritional Protocol: Complete elimination of all refined sugars, honey, maple syrup, agave, artificial sweeteners, and high-glycaemic carbohydrates. Removal of all alcohol (yeast substrate; acetaldehyde burden). Elimination of fermented foods temporarily (histamine and yeast loading during initial die-off). Introduction of a whole-foods, low-glycaemic-load dietary pattern centred around non-starchy vegetables, adequate protein (1.2 g/kg body weight — approximately 110 g daily from fish, poultry, eggs, and legumes), and healthy fats (olive oil, avocado, coconut oil). Cruciferous vegetables daily for hepatic sulphation support. Two litres of filtered water with lemon daily. The dietary shift served three purposes: starving yeast of its primary substrate (glucose), reducing post-prandial insulin surges, and providing nutrient density to begin correcting the deficiencies identified.

Blood Sugar Stabilisation:

• Chromium picolinate: 400 µg twice daily with meals — enhances insulin receptor signalling through chromodulin binding [1]
• Alpha-lipoic acid: 300 mg twice daily — improves insulin sensitivity via AMPK activation and provides antioxidant support for hepatic detoxification [2]
• Magnesium glycinate: 200 mg twice daily — addresses RBC magnesium deficiency; magnesium is a co-factor in over 300 enzymatic reactions including tyrosine kinase activity at the insulin receptor [3]

Initial Antifungal Support (gentle start to manage die-off):

• Caprylic acid: 500 mg twice daily with meals — medium-chain fatty acid that disrupts Candida cell membranes and penetrates biofilms [4]
• Oregano oil (standardised to 70% carvacrol): 2 drops in water twice daily after food — carvacrol inhibits Candida albicans morphogenesis (the yeast-to-hyphal transition), adhesion, and biofilm formation [5]

Gut Barrier Support:

• L-Glutamine powder: 5 g twice daily on an empty stomach — primary fuel for enterocytes; supports tight junction protein expression [6]

Die-Off Management (commenced Day 3): David experienced moderate Herxheimer-type symptoms (headache, fatigue exacerbation, joint aching) from Days 3-7 of Phase 1. These were managed with increased hydration (3 L daily), Epsom salt baths for sulphate conjugation support, and a temporary reduction in caprylic acid to 500 mg once daily for three days before returning to the full dose. Activated charcoal (1,000 mg at bedtime, 2 hours away from all other supplements) was introduced from Day 5 for toxin binding.

Phase 2: Repair and Replenish (Weeks 5-8)

With die-off symptoms resolved by the end of Week 3 and David reporting notably reduced sugar cravings ("I walked past the biscuit aisle and didn't even notice them — that's never happened"), Phase 2 escalated the antifungal protocol and introduced microbiome restoration.

Escalated Antifungal Protocol:

• Caprylic acid: 1,000 mg three times daily with meals [4]
• Oregano oil: 4 drops in water twice daily after food [5]
• Berberine HCl: 500 mg three times daily with meals — a broad-spectrum plant alkaloid with documented effects against Candida spp. (inhibits biofilm formation, disrupts cell membrane integrity) and independent metabolic benefits: AMPK activation, improved insulin sensitivity, and reduced hepatic gluconeogenesis [7]

Microbiome Restoration:

• Saccharomyces boulardii (CNCM I-745): 5 billion CFU twice daily on an empty stomach — a non-pathogenic probiotic yeast that directly antagonises Candida albicans by inhibiting filamentation (hyphal transition), adhesion to intestinal epithelium, and biofilm formation [8]. Its probiotic properties include enhancing sIgA production and degrading C. albicans-secreted virulence factors.
• Multi-strain probiotic (including Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus GG, Bifidobacterium lactis Bi-07): 25 billion CFU once daily with breakfast — dosed at least 2 hours apart from antimicrobials to ensure viability

Hepatic and Detoxification Support:

• N-Acetyl Cysteine (NAC): 600 mg twice daily — glutathione precursor supporting Phase II hepatic conjugation pathways and reducing the elevated β-glucuronidase
• Milk thistle (Silybum marianum, standardised to 80% silymarin): 250 mg twice daily — hepatoprotective; supports Phase I/II balance and glutathione synthesis

Continued Nutritional Replenishment:

• Vitamin D3: 5,000 IU daily with the fattiest meal (to optimise absorption) — targeting serum 25(OH)D of >100 nmol/L [9]
• Zinc picolinate: 30 mg daily with food — addressing the low-normal serum zinc; zinc is essential for intestinal barrier integrity, immune function, and insulin signalling
• Methylated B-complex (activated forms: methylfolate, methylcobalamin, pyridoxal-5-phosphate, riboflavin-5-phosphate): 1 capsule daily — bypassing any potential methylation polymorphisms and directly supporting energy metabolism
• Omega-3 fatty acids (EPA 1,200 mg, DHA 800 mg): 2 softgels daily — anti-inflammatory, supporting insulin receptor membrane fluidity and endothelial function [10]

Phase 3: Rebalance and Integrate (Weeks 9-12)

Phase 3 shifted the emphasis from active treatment to sustainable integration and metabolic resilience.

Dietary Reintroduction and Metabolic Flexibility: Gradual reintroduction of low-glycaemic fruits (berries, green apples), legumes (lentils, chickpeas), and gluten-free whole grains (quinoa, buckwheat) in small portions — monitoring for any symptom recurrence. Fermented foods cautiously reintroduced (1 tablespoon sauerkraut daily initially, titrated up). Continued avoidance of refined sugar, alcohol, and ultra-processed foods. Emphasis on meal timing: 12-hour overnight fasting window (finishing dinner by 7 p.m., breakfast at 7 a.m.) to support circadian insulin sensitivity and allow overnight gut epithelial repair.

Exercise Prescription — Movement as Insulin Sensitiser:

• Daily walking: 8,000-10,000 steps, with one 20-minute brisk walk after the largest meal (post-prandial glucose disposal)
• Resistance training: two sessions weekly (bodyweight exercises initially — squats, press-ups, lunges, planks — progressing to resistance bands by Week 11)
• This combination exploits both AMPK-dependent (acute exercise) and GLUT4-translocation-dependent (post-exercise) pathways for glucose uptake, independent of insulin signalling [11]

Stress Modulation — HPA Axis Restoration:

• Morning: 5 minutes of box breathing (4-second inhale, 4-second hold, 4-second exhale, 4-second hold), practised immediately on waking before checking his phone
• Evening: 10-minute guided body-scan meditation using an audio app — framed as "mental skills training for focus," aligning with David's performance-oriented mindset
• Alcohol abstinence continued — framed as a positive choice for metabolic health rather than a deprivation
• Screen curfew: no screens after 9 p.m., replaced with reading (David chose military history)

Maintenance Antifungal and Gut Support:

• Saccharomyces boulardii continued at 5 billion CFU once daily
• Multi-strain probiotic continued at maintenance dose (15 billion CFU daily)
• Caprylic acid reduced to 500 mg once daily as maintenance antifungal — to be reviewed at the 16-week follow-up

Outcomes at 12 Weeks

David returned for his 12-week outcomes consultation in May 2026. The transformation was objectively measurable across every assessment domain and viscerally apparent in his presentation — he walked into the clinic upright, engaged, and visibly leaner.

Anthropometric and Metabolic Changes:

The HOMA-IR reduction from 4.8 to 1.7 represented a shift from severe insulin resistance to the upper threshold of insulin sensitivity — a clinically meaningful reversal achieved without pharmacotherapy.

Repeat Functional Testing:

• GI-MAP: Candida albicans reduced to 0.8 × 10³ (below reference threshold); Candida spp. at 0.6 × 10³
• Faecal zonulin: reduced to 112 ng/mL (approaching the normal reference of <107 ng/mL) — indicating significant restoration of intestinal barrier integrity
• Secretory IgA: increased to 682 µg/g — mucosal immune function restored to normal range
• β-glucuronidase: reduced to 2,940 U/g (within normal range)
• D-Arabinitol: reduced to 18 mmol/mol creatinine (below reference threshold of 29)
• Serum magnesium (RBC): 1.92 mmol/L (within optimal range)
• Vitamin D (25-OH): 108 nmol/L (within optimal range)
• Serum B12: 482 pg/mL (improved substantially with methylated B12 supplementation and gut healing)

Functional Health Matrix Re-Score:

Total Final Matrix Score: 26/35 (+14 points; 117% improvement)

The greatest gains were in Assimilation (the therapeutic root), Energy Production (mitochondrial efficiency restored), and Biotransformation (hepatic detoxification pathways unburdened by alcohol and yeast metabolites). The Communication node, whilst significantly improved, would require ongoing attention — insulin signalling was restored but David's genetic and environmental predisposition to metabolic syndrome remained.

Wheel of Life Re-Score:

Total Final Wheel of Life Score: 53/80 (+22 points; 71% improvement)

The most dramatic shifts were in Nutrition (+6 points) and Movement (+4 points) — domains that had been profoundly impaired and where David's commitment to the protocol produced rapid, tangible results that reinforced adherence. Sleep improved as nocturnal hypoglycaemia resolved and the evening screen curfew consolidated his circadian rhythm. Stress Management improved modestly but genuinely — David reported that the morning breathing practice had begun to feel "as automatic as brushing my teeth."

Patient Testimonial: "I didn't really believe any of this at the start, to be honest. I'm an IT guy — I like things that are measurable, and nobody had measured anything on me before except my blood sugar. But when you showed me the stool test — that there was literally too much yeast in my gut — and then explained how that was driving the insulin problem, it clicked. Three months later, I've lost over a stone and a half, I don't crave sugar at all, my head is clearer than it's been in years, and my GP has said I don't need metformin. That white coating on my tongue? Gone. The interesting bit — and I didn't expect this — is that I don't actually miss the beer. I thought that would be the hardest part, but once the cravings disappeared, it just wasn't an issue."

Maintenance Plan: David was transitioned to a maintenance protocol: continued whole-foods low-glycaemic-load diet with the 12-hour overnight fast, twice-weekly resistance training and daily walking, Saccharomyces boulardii 5 billion CFU daily, multi-strain probiotic 15 billion CFU daily, magnesium glycinate 200 mg daily, omega-3 fatty acids 2 g daily, and vitamin D3 2,000 IU daily (maintenance dose post-repletion). Caprylic acid was discontinued, with a plan for a repeat GI-MAP at 24 weeks to confirm sustained mycobiome balance. He was advised to limit alcohol to occasional moderate intake (1-2 drinks, maximum once weekly) and to never take antibiotics without concurrent S. boulardii and probiotic support. A 6-month follow-up was scheduled for November 2026.

Clinical Pearls

1. The gut mycobiome is a metabolic organ. David's case illustrates that fungal dysbiosis is not merely a local GI nuisance — it is a systemic metabolic driver. Emerging evidence demonstrates that Candida albicans overgrowth can directly induce insulin resistance through fungal metabolite-mediated inflammatory cascades [12]. Treating metabolic syndrome without assessing the gut mycobiome is incomplete root-cause medicine.

2. Holistic eradication, not pharmaceutical monotherapy, resolves chronic candidiasis. David had failed two courses of fluconazole because the drug killed yeast without addressing the ecosystem that permitted overgrowth — the high-sugar diet, the depleted microbiome, the compromised gut barrier, and the insulin resistance that bathed his intestinal mucosa in glucose. Antifungal pharmaceuticals have their place, but for chronic, non-invasive candidiasis in an immunocompetent host, the functional medicine 5R framework (Remove, Replace, Reinoculate, Repair, Rebalance) is more effective and more durable.

3. The oral cavity is a window to the gut mycobiome. David's persistent oral thrush was a visible biomarker that no one had connected to his metabolic health. In clinical practice, oral candidiasis in a non-immunocompromised, non-steroid-using adult should prompt investigation of the gut mycobiome and glycaemic status — the tongue is telling you something about the small intestine.

4. Saccharomyces boulardii is an under-utilised tool in metabolic medicine. Most clinicians associate S. boulardii with antibiotic-associated diarrhoea and Clostridioides difficile prevention. Its direct antagonism of Candida albicans — inhibiting the yeast-to-hyphal transition that is the critical virulence switch [8,13] — and its capacity to enhance secretory IgA production make it a cornerstone agent in cases where fungal dysbiosis and metabolic syndrome co-exist. It competes with Candida in the mycobiome niche whilst simultaneously supporting bacterial microbiome restoration.